Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programmes -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and programme funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Netherlands?
GlobalGov holds 565 pharmaceuticals records from 187 distinct buying organisations in Netherlands. The most frequent publishers are Gemeente Den Haag (20 records); Gemeente Rotterdam (19 records); Ministerie van Defensie (18 records); Gemeente Leeuwarden (14 records); Gemeente Maastricht (12 records); Gemeente Eindhoven (9 records). Between them the 6 largest account for 16% of everything published, so buying here is spread across many separate authorities.
| Buying organisation | Records | Share |
|---|---|---|
| Gemeente Den Haag | 20 | 3.5% |
| Gemeente Rotterdam | 19 | 3.4% |
| Ministerie van Defensie | 18 | 3.2% |
| Gemeente Leeuwarden | 14 | 2.5% |
| Gemeente Maastricht | 12 | 2.1% |
| Gemeente Eindhoven | 9 | 1.6% |
What are pharmaceuticals contracts worth in Netherlands?
182 of the 565 records publish a contract value. The median is $2.2M and the largest single published value is $1.7B. By size, 23 under $100k, 33 between $100k and $1M, 91 between $1M and $10M, 35 above $10M. The remaining 383 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 23 | 13% |
| between $100k and $1M | 33 | 18% |
| between $1M and $10M | 91 | 50% |
| above $10M | 35 | 19% |
How long do bidders get to respond to pharmaceuticals tenders in Netherlands?
Across the 120 Netherlands pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 50 days. A quarter of them allowed 42 days or fewer and a quarter stayed open for more than 63. Not one of them closed within a fortnight of being published, so the window on this market is consistently workable.
How often are pharmaceuticals tenders published in Netherlands?
Netherlands publishes about 14 notices a month in this category, 163 in the last twelve months. That is 94% more than the 84 published in the twelve months before that. Over the last three years there were 329, spread across 65 separate months of activity since 21 September 2016. May is historically the busiest month. No new notice has been published in this category since 26 May 2026, 128 days ago, so treat the figures above as a record of the market rather than as this week's pipeline.
How does Netherlands compare with other pharmaceuticals markets?
Among the 39 countries where GlobalGov holds a comparable pharmaceuticals market, Netherlands ranks 12th by number of records. The largest is Germany (4,115 records against 565 here). Within Netherlands itself, pharmaceuticals is the 19th largest of the 63 procurement categories tracked here.
Where do the Netherlands pharmaceuticals records on this page come from?
These 565 records are collected from 1 official source: TED (565). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-10-01.
Most recent Pharmaceuticals tenders in Netherlands
None of these are open for bids now — they are the most recent records GlobalGov holds for this market, kept here so the shape of a typical pharmaceuticals notice in Netherlands is visible. Set an alert to be told when the next one opens.
Netherlands – Guidance services – begeleiding voor inzet Welbevinden+
Netherlands – Counselling services – Uitvoering Vroeg signalering Wet Gemeentelijke Schuldhulpverlening (WGS)
Netherlands – Medical gases – Medische gassen
Netherlands – Explosives – Charge demolition pressure 9 kg TNT
Other procurement categories in Netherlands
Pharmaceuticals procurement in other markets
Never Miss a Netherlands Government Contract
Finding Netherlands tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial